A-501, Venus Vasant Valley, Filmcity Road, Malad (East), Mumbai – 400097

March 12, 2024

To,

Securities and Exchange Board of India

Plot No. C4-A, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, Maharashtra.

Sub: Report under Regulation 10(7) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Dear Sir/Madam,

Please find enclosed herewith the copy of the Report under Regulation 10(7) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 in respect of acquisition of 73,125 equity shares of Supriya Lifescience Limited from Dr. Saloni Wagh.

This is for your kind information and record.

Thanking you,

Yours faithfully,

SHIVANI Digitally signed by SHIVANI SATISH WAGH

SATISH WAGH

Date: 2024.03.12
11:42:37 +05:30'

Shivani Wagh Acquirer

Encl: As above

CC:

1. BSE Limited

Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai Scrip Code - 543434

2. National Stock Exchange of India Ltd

Exchange Plaza, 5th Floor, Plot No. C/1, G block, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051 **Scrip ID – SUPRIYA**

3. The Company Secretary Supriya Lifescience Limited 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400063.

Regulation 10(7) – Report to SEBI in respect of any acquisition made in reliance upon exemption provided for in regulation 10(1)(a)(i) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

1	Gen	eral Details				
	a.	Name, address, telephone no., e-mail ofacquirer(s) {In case there are multiple acquirers, provide full	Shivani Wagh Address: A-501, Venus Vasant Valley, Filmcity Road Malad (East), Mumbai – 400097. Telephone No.: 022 40332727 Email: shivani@supriyalifescience.com			
	b.	Whether sender is the acquirer (Y/N)	Yes			
	c.	If not, whether the sender is duly authorized by the acquirer to act on his behalf in this regard (enclose copy of such authorization)	NA			
	d.	Name, address, Tel no. and e-mail of thesender, if sender is not the acquirer	NA			
2	Com	ppliance of Regulation 10(7)				
	a.	Date of report	12.03.2024			
	b.	Whether report has been submitted to SEBI within 21 working days from the date of the acquisition	Yes, the report has been submitted within 21 working days from the date of acquisition.			
	c.	Whether the report is accompanied with feesas required under Regulation 10(7)	Yes, the details are enclosed herewith.			
3	Compliance of Regulation 10(5)					
	a.	Whether the report has been filed with the Stock Exchanges where the shares of the Company are listed, atleast 4 working days before the date of the proposed acquisition	Yes			
	b.	Date of Report	19.12.2023			
4	Com	ppliance of Regulation 10(6)				
	a.	Whether the report has been filed with the Stock Exchanges where the shares of the Company are listed within 4 working days after the date of the proposed acquisition	Yes			
	b.	Date of Report	28.02.2024			
5	Deta	Details of the Target Company (TC)				
	a.	Name & address of TC	Supriya Lifescience Limited Regd. Office: 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063.			

	b.	Name of the Stock Exchange(s) where the shares of the TC are listed	National Stock E BSE Limited	Exchange of Ir	ndia Limited	
6	Deta	ils of the acquisition	•			
	a.	Date of acquisition	26.02.2024			
	b.	Acquisition price per share (in Rs.)	Not applicable { Gift between more relative)}.			
	c.	Regulation which would have been triggered an open offer, had the report not been filed under Regulation 10(7). (whether Regulation 3(1), 3(2), 4 or 5)	Regulation 3(2)			
	d.	Shareholding of acquirer(s) and PAC individually	Before the ac	equisition	After the a	equisition
		in TC (in terms of no. & as a percentage of the total share/voting capital of the TC)(*)	No. ofShares	% w.r.t total share capital of TC	No. of Shares	% w.r.t totalshare capital of TC
		Name of the acquirer(s) / PAC (**)	Plea	se refer to the	Annexure - 1	1
	e. Shareholding of seller/s in TC (in terms of no.& a		Before the ac	After the a	equisition	
		a percentage of the total share/voting capital of the TC)	No. ofShares	% w.r.t total share capital of TC	No. of Shares	% w.r.t totalshare capital of TC
		Name of the Seller(s)(**)	Plea	se refer to the	Annexure - 1	l
7		rmation specific to the exemption category to w)(a)(i)	hich the instan	t acquisition	belongs-Reg	gulation
	a.	Provide the names of the seller(s)	Dr. Saloni Wagh	, member of l	Promoter Gro	up
	b.	Specify the relationship between the acquirer(s) and the seller(s).	Ms. Shivani Wag Hence, they are in member of prom	mmediate rela		
	c.	Confirm whether the acquirer(s) and the seller(s) are 'immediate relatives' as defined in the Regulation 2(l).	Yes, the acquire of immediate relationship the SAST Regula	atives stated u		
	d.	weighted average market price (VWAP) of such	Not Applicable. The shares were consideration wa		way of Gift.	Therefore, no

e.	If the shares of the TC are infrequentlytraded, the price of such shares as determined in terms of clause (e) of sub-regulation (2) of regulation 8.	Not Applicable. The shares were transferred by way of Gift. Therefore, no consideration was involved.
f.	Confirm whether the acquisition price per share is not higher by more than twenty-five percent of the price as calculated in (d) or (e) above as applicable.	Not Applicable. The shares were transferred by way of Gift. Therefore, no consideration was involved.
g.	Date of issuance of notice regarding the proposed acquisition to the stock exchanges where the TC is listed.	19.12.2023
h.	complied with the provisions of Chapter V of the Takeover Regulations (corresponding provisions of the repealed TakeoverRegulations 1997) (Y/N). If yes, specify applicable regulation(s) as well as	Yes, the acquirer as well as seller have complied with the provisions of Chapter V of the Takeover Regulations, 2011. The disclosure filed under Regulation 29(2) on 27.02.2024 is enclosed herewith for the current transaction.
i.		I hereby confirmed that all the conditions specified under Regulation 10(1)(a)(i) with respect to exemptions has been duly complied with. Such declaration was given along with the report under Regulation 10(6) to the Stock Exchanges 28.02.2024.

I/We hereby declare that the information provided in the instant report is true and nothing hasbeen concealed there from.

Signature:

SHIVANI Digitally signed by SHIVANI SATISH WAGH Date: 2024.03.12 11:43:23 +05'30'

Shivani Wagh Date: 12.03.2024

NOTE:

- (*) In case, percentage of shareholding to the total capital is different from percentage of voting rights, indicate percentage of shareholding and voting rights separately.
- (**) Shareholding of each entity shall be shown separately and then collectively in a group.

Annexure- 1

Sha	areholding details	Before the	acquisition	After the a	cquisition
		No. of Shares	% w.r.t total share capital of TC	No. ofShares	% w.r.t total share capital of TC
	Name of the acquirer(s) / PAC				
a.	Name of the acquirer				
	Shivani Satish Wagh	29,250	0.04	1,02,375	0.13
b.	Name of the PACs (other than Seller)				
	Satish Waman Wagh	5,44,41,205	67.64	5,44,41,205	67.64
	Smita Satish Wagh	3,21,750	0.40	3,21,750	0.40
	Supriya Pharmaceuticals	10	0.00	10	0.00
c.	Name of the seller:				
	Saloni Satish Wagh	1,75,500	0.22	1,02,375	0.13
	Total (a+b+c)	54967715	68.30	54967715	68.30

February 27, 2024

To,

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai - 400 001

Scrip Code - 543434

To,

National Stock Exchange of India Ltd

Exchange Plaza, Plot No. C/1, G block,

Bandra-Kurla Complex,

Bandra (E), Mumbai - 400 051

Scrip ID - SUPRIYA

Sub.: Disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Dear Sir / Madam,

Please find attached herewith the disclosure under the Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, in connection with the inter-se-transfer of 73,125 equity shares in off market transaction by way of gift from Dr. Saloni Satish Wagh to Ms. Shivani Satish Wagh.

This is for your kind information and record.

Thanking you,

Yours faithfully,

Shivani Satish Wagh

Acquirer & member of Promoter Group

Encl: As above

CC:

The Company Secretary
Supriya Lifescience Limited
207/208, Udyog Bhavan, Sonawala Road,
Goregaon (East), Mumbai – 400 063.

Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Supriya Lifescience Limited Acquirer: Shivani Satish Wagh Person Acting in Concert (PAC): Dr. Satish Waman Wagh Mrs. Smita Satish Wagh Dr. Saloni Satish Wagh			
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer				
Wild distribution	Supriya Phar	0		
Whether the acquirer belongs to Promoter/ Promoter group	Yes			
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited National Stock Exchange of India Limited			
Details of the acquisition/ Disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)	
Before the acquisition under consideration,				
holding of:				
a) Shares carrying voting rights Seller:				
Dr. Saloni Satish Wagh	1,75,500	0.22	0.22	
Acquirer:				
Ms. Shivani Satish Wagh	29,250	0.04	0.04	
Person Acting in Concert (PAC):				
Dr. Satish Waman Wagh	5,44,41,205	67.64	67.64	
Mrs. Smita Satish Wagh	3,21,750	0.40	0.40	
Supriya Pharmaceuticals	10	0.00	0.00	
Shares in the nature of encumbrance (pledge/	A EV			
lien/ non-disposal undertaking/ others) Voting rights (VR) otherwise than by equity shares				
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)				
e) Total (a+b+c+d)	5,49,67,715	68.30	68.30	
	2, 2, 3, 7, 10	30.00	00.00	

	cquisition/ sale			
	arrying voting rights acquired/sold	TTO WAR		
Seller:				
Dr. Salo	ni Satish Wagh	(73,125)	(0.09)	(0.09)
	carrying voting rights acquired:			
Ms. Shiv	vani Satish Wagh	73,125	0.09	0.09
	uired otherwise than by shares			
	s/convertible securities/any other			
	ent that entitles the acquirer to receive			
	arrying voting rights in the TC (specify			
	in each category) acquired/sold			
	ncumbered / invoked/released by the			
acquirer Total (a	hhatd)			
:) 10tai (a	-о-с-а)	4		•
	equisition/sale, holding of:			
-	arrying voting rights			
Seller:	ai Catial Wast	1.00.275	0.10	
Dr. Saloi	ni Satish Wagh	1,02,375	0.13	0.13
Acquire	r:			
	vani Satish Wagh	1,02,375	0.13	0.13
Person A	Acting in Concern (PAC):			
	sh Waman Wagh	5,44,41,205	67.64	67.64
	ita Satish Wagh	3,21,750	0.40	0.40
Supriya	Pharmaceuticals	10	0.00	0.00
b) Shares en	ncumbered with the acquirer			
	erwise than by shares			
	s/convertible securities/any other			
	nt that entitles the acquirer to receive			
	arrying voting rights in the TC (specify			
	n each category) after acquisition			
e) Total (a+	-b+c+d)	5,49,67,715	68.30	68.30
Mode of acc	quisition / sale (e.g. open market / off-	Off market Inte	er-se transfer of	shares in the forr
market / pu	blic issue / rights issue / preferential nter-se transfer etc).	of a gift		
	nisition / sale of shares / VR or date of			
	intimation of allotment of shares, applicable.		26/02/2024	
No. of the contract of the con	capital / total voting capital of the TC	Equity Sha	re Capital of Rs	.16,09,65,600
The state of the s	aid acquisition / sale.		f 8,04,82,800 Ed Rs.2/- each	
Equity share	e capital/ total voting capital of the TC	Equity Sha	re Capital of Rs	.16,09,65,600
	l acquisition / sale.		f 8,04,82,800 E	

Rs.2/- each

Total diluted share/voting	capital	of	the	TC	after
the said acquisition.					

Equity Share Capital of Rs.16,09,65,600 consisting of 8,04,82,800 Equity Shares of Rs.2/- each

(*) Total share capital/voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Regulation 31 of the SEBI LODR.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Shivani Satish Wagh

Acquirer

Date: February 27, 2024 Place: Mumbai

February 28, 2024

To,

BSE Limited

Phiroze Jeejeebhov Towers,

Dalal Street,

Mumbai - 400 001

Scrip Code - 543434

To.

National Stock Exchange of India Ltd

Exchange Plaza, Plot No. C/1, G block,

Bandra-Kurla Complex,

Bandra (E), Mumbai - 400 051

Scrip ID - SUPRIYA

Sub: Disclosure under Regulation 10(6) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Ref.: Prior intimation submitted under Regulation 10(5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 dated December 19, 2023.

Dear Sir / Madam,

With regard to the captioned subject and in continuation to my prior intimation submitted under Regulation 10(5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 dated December 19, 2023, please find enclosed herewith the disclosure under Regulation 10(6) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 with respect to the acquisition of 73,125 (Seventy Three Thousand One Hundred and Twenty-Five) equity shares of Supriya Lifescience Limited (Target Company) from Dr. Saloni Satish Wagh, member of Promoter group Whole Time Director of Target Company, details of which are enclosed herewith.

The said acquisition is pursuant to off market inter-se transfer of shares between member of Promoter Gorup (immediate relatives), as specified in Regulation 10(1)(a)(i) and (ii) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 by way of Gift.

This is for your kind information and record.

Thanking you,

Yours faithfully,

Shiyani Satish Wagh

Acquirer & member of Promoter Group

Encl: As above

CC:

The Company Secretary
Supriya Lifescience Limited
207/208, Udyog Bhavan, Sonawala Road,
Goregaon (East), Mumbai – 400 063.

		nce upon exemption provided for in Regulation 10 of SEBI	
1.	Name of the Target Company (TC)	Supriya Lifescience Limited	
2.	Name of the acquirer(s)	Shivani Satish Wagh	-
-	Name of the stock exchange who shares of the TC are listed		
4.		ng rationale, Transfer of 73,125 Equity Shares i.e. 0.09% of total shar capital as per the latest shareholding pattern of the TC fr Saloni Satish Wagh to Ms. Shivnai Satish Wagh. (Ms. S Satish Wagh is the sister of Dr. Saloni Satish Wagh). Inter-se transfer of shares amongst member of Promoter (immediate relatives) without consideration by way of G	om I hivn: Grou
5.	Relevant regulation under which the is exempted from making open offer.	Under Regulation 10(1)(a)(i) and (ii) of SEBI (Substanti Acquisition of Shares and Takeovers) Regulations, 2011	
6.	Whether disclosure of propose acquisition was required to be ma regulation 10 (5) and if so, - whether disclosure was made and was made within the timeline specuader the regulations date of filing with the stock	Intimation to Stock Exchanges in respect of acquisition of Regulation 10(1)(a) of SEBI (Substantial Acquisition of and Takeovers) Regulations, 2011. Yes, the discoloure was made within the timeline specific the regulations.	under Shar ed ur
		The same was fried on 19.12.2023 with stock exchanges	
7.	Details of acquisition	Disclosures required to be made under regulation 10(5) are actually made	und
7.		Disclosures required to be made under Whether the disclosures regulation 10(5)	und
7.	Details of acquisition a. Name of the transferor / seller	Disclosures required to be made under regulation 10(5) regulation 10(5) are actually made Dr. Saloni Satish Wagh Yes	und
7.	Details of acquisition a. Name of the transferor / seller	Disclosures required to be made under regulation 10(5) are actually made Dr. Saloni Satish Wagh Yes 26.02.2024 Yes	und
7.	a. Name of the transferor / seller b. Date of acquisition c. Number of shares/ voting rights of the acquisitions from each	Disclosures required to be made under regulation 10(5) are actually made Dr. Saloni Satish Wagh Yes 26.02.2024 Yes in respect 73,125 Whether the disclosures regulation 10(5) are actually made	und

8.	Shareholding details		Pre-Trai	Pre-Transaction		ansaction
			No. of shares held	% w.r.t total share capital of TC	No. of shares held	% w.r.t total share capital of TC
	a	Each Acquirer / Transferee(*) along with PAC			-	
		Ms. Shivani Satish Wagh	29,250	0.04	1,02,375	0.13
		Dr. Satish Waman Wagh	5,44,41,205	67.64	5,44,41,205	67.64
		Mrs. Smita Satish Wagh	3,21,750	0.40	3,21,750	0.40
		Supriya Pharmaceuticals	10	0.00	10	0.00
	b	Each Seller / Transferor				
		Dr. Saloni Satish Wagh	1,75,500	0.22	1,02,375	0.13
		Total	5,49,67,715	68.30	5,49,67,715	68.30

Note:

The above disclosure shall be signed by the acquirer mentioning date & place. In case, there is more than one acquirer, the report shall be signed either by all the persons or by a person duly authorized to do so on behalf of all the acquirers.

Shivani Wagh Acquirer

^(*) Shareholding of each entity shall be shown separately and then collectively in a group.

February 27, 2024

To,

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai - 400 001

Scrip Code - 543434

To,

National Stock Exchange of India Ltd

Exchange Plaza, Plot No. C/1, G block,

Bandra-Kurla Complex,

Bandra (E), Mumbai - 400 051

Scrip ID - SUPRIYA

Sub.: Disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Dear Sir / Madam,

Please find attached herewith the disclosure under the Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, in connection with the inter-se-transfer of 73,125 equity shares in off market transaction by way of gift from Dr. Saloni Satish Wagh to Ms. Shivani Satish Wagh.

This is for your kind information and record.

Thanking you,

Yours faithfully,

Shivani Satish Wagh

Acquirer & Member of Promoter Group

Encl: As above

CC:

The Company Secretary
Supriya Lifescience Limited
207/208, Udyog Bhavan, Sonawala Road,
Goregaon (East), Mumbai – 400063.

Disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A- Details of the Acquisition

Name of the Target Company (TC)	Supriya Lifes	science Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Acquirer: Shivani Satish Wagh Person Acting in Concert (PAC): Dr. Satish Waman Wagh Mrs. Smita Satish Wagh Dr. Saloni Satish Wagh Supriya Pharmaceuticals			
Whether the acquirer belongs to Promoter/ Promoter group	Yes			
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited National Stock Exchange of India Limited			
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)	
Before the acquisition under consideration, holding of acquirer along with PACs: a) Shares carrying voting rights				
Acquirer: Shivani Satish Wagh	29,250	0.04	0.04	
Person Acting in Concert (PAC): Dr. Satish Waman Wagh Mrs. Smita Satish Wagh Dr. Saloni Satish Wagh Supriya Pharmaceuticals Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others)	5,44,41,205 3,21,750 1,75,500 10	67.64 0.40 0.22 0.00	67.64 0.40 0.22 0.00	
v) Voting rights (VR) otherwise than by equity shares				

d) e)	Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category) Total (a+b+c+d)	5,49,67,715	68.30	68.30
131	tails of acquisition:			
a)	Shares carrying voting rights acquired	MI ENGL		
	Shivani Satish Wagh	73,125	0.09	0.09
b) c) d)	VRs acquired otherwise than by shares Warrants/ convertible securities/ any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/ sold Shares encumbered / invoked/ released by the			
e)	acquirer Total (a+b+c+d)	73,125	0.09	0.09
wi	ter the acquisition holding of acquirer along th PACs of: Shares carrying voting rights			
	Acquirer:			
	Shivani Satish Wagh	1,02,375	0.13	0.13
	Person Acting in Concern (PAC):			
	Dr. Satish Waman Wagh	5,44,41,205	67.64	67.64
	Mrs. Smita Satish Wagh	3,21,750	0.40	0.40
	Dr. Saloni Satish Wagh	1,02,375	0.13	0.13
	Supriya Pharmaceuticals	10	0.00	0.00
c)	VRs otherwise than by shares Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition			
d)	Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/ others)			ALS PIEW
e)	Total (a+b+c+d)	5,49,67,715	68.30	68.30
Me	ode of acquisition / sale (e.g. open market / off- arket / public issue / rights issue / preferential otment / inter-se transfer etc).		er-se transfer of	shares in the form
Sa tin	lient features of the securities acquired including ne till redemption, ratio at which it can be inverted into equity shares, etc.		I Equity Shares ne existing Equi Company.	shall rank pari- ty Shares of the

Date of acquisition of/ date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	26/02/2024
Equity share capital / total voting capital of the TC before the said acquisition / sale.	Equity Share Capital of Rs.16,09,65,600 consisting of 8,04,82,800 Equity Shares of Rs.2/- each
Equity share capital/ total voting capital of the TC after the said acquisition / sale.	Equity Share Capital of Rs.16,09,65,600 consisting of 8,04,82,800 Equity Shares of Rs.2/- each
Total diluted share/voting capital of the TC after the said acquisition.	Equity Share Capital of Rs.16,09,65,600 consisting of 8,04,82,800 Equity Shares of Rs.2/- each

Date: February 27, 2024 Place: Mumbai

Acquirer

Part-B**

Name of the Target Company: Supriya Lifescience Limited

Name(s) of the Person and Persons Acting in Concert (PAC) with the person	Whether the person belongs to Promoter/ Promoter group	PAN of the person and PACs	
Dr. Satish Waman Wagh	Promoter	AAAPW7907N	
Mrs. Smita Satish Wagh	Promoter Group	AANPW0379F	
Dr. Saloni Satish Wagh	Promoter Group	ABRPW5364K	
Ms. Shivani Satish Wagh	Promoter Group	ABRPW5365J	
Supriya Pharmaceuticals	Promoter Group	AEKFS7615F	

- (*) Total share capital/voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Regulation 31 of the SEBI LODR.
- (**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.
- (***) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated..

Shiyani Satish Wagh

Acquirer

Date: February 27, 2024

Place: Mumbai

December 19, 2023

To,

BSE Limited

1st Floor,

New Trading Ring, Rotunda Building,

Phiroze Jeejeebhoy Towers.

Dalal Street, Mumbai

Scrip Code - 543434

To,

National Stock Exchange of India Ltd

Exchange Plaza, 5th Floor, Plot No. C/1, G block, Bandra-Kurla Complex.

Bandra (E),

Mumbai - 400 051

Scrip ID - SUPRIYA

Sub: Submission of disclosure required under Regulation 10(5) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Dear Sir/Madam.

I hereby submit the disclosure under Regulation 10(5) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 for acquisition of 73,125 (Seventy-Three Thousand One hundred and Twenty-Five) shares of Supriya Lifescience Limited from Dr. Saloni Satish Wagh (Sister and forming part of Promoter group), details of which are enclosed herewith as Annexure 1.

Please note that this transaction, being inter-se transfer of shares amongst the immediate relatives and Promoter Group, falls within the exemptions provided under Regulation 10(1)(a)(i) and (ii) of the SEBI (SAST) Regulations, 2011.

The Aggregate holding of promoter & promoter group before and after the above inter-se transaction will remain the same.

This is for your kind information and record.

Thanking you,

Yours faithfully.

Shivan Satish Wagh

Acquirer and member of Promoter Group

Date: December 19, 2023

Place: Mumbai Encl: As above

CC: Supriya Lifescience Limited

207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400063.

Annexure 1

Format for Disclosures under Regulation 10(5) – Intimation to Stock Exchanges in respectof acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

1.	N	ame of the Target Company (TC)	Supriya Lifescience Limited		
2.	N	ame of the acquirer(s)	Shiyani Satish Wash		
3.	pi	Thether the acquirer(s) is/ are promoters of the TC rior to the transaction. If not, nature of relationship association with the TC or its promoters	Vas		
4.	Details of the proposed acquisition				
	a.	Name of the person(s) from whom shares are to be acquired	Dr. Saloni Satish Wagh		
		Proposed date of acquisition	On or After 27.12.2023		
		Number of shares to be acquired from each person mentioned in 4(a) above	73,125 Equity Shares		
		Total shares to be acquired as % of share capital of TC	0.09 % of total share capital as per the lates shareholding pattern of the Company.		
		Price at which shares are proposed to be acquired	Not Applicable (Inter se transfer of shares among the Promoter Group without consideration by way of Gift)		
77.		Rationale, if any, for the proposed transfer	Inter-se transfer of shares amongst Promote Group without consideration		
5.	Relevant sub-clause of regulation 10(1)(a) under which the acquirer is exempted from making open offer		Under Regulation 10(1)(a)(i) and (ii) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011		
6.	If, frequently traded, volume weighted averagemarket price for a period of 60 trading days preceding the date of issuance of this notice as traded on the stock exchange where the maximum volume of trading in the shares of the TC are recorded during such period.		NA		
7.	If in-frequently traded, the price as determined in terms of clause (e) of sub-regulation (2) of regulation 8.		NA		
8.	Declaration by the acquirer, that the acquisition price would not be higher by more than 25% of the price computed in point 6 or point 7 as applicable.		Not Applicable since proposed transfer is way of gift, hence, acquisition price is zero		

A agh

9.	Declaration by the acquirer, that the transferor and transferee have complied / will comply with applicable disclosure requirements in Chapter V of the Takeover Regulations, 2011 (corresponding provisions of the repealed Takeover Regulations 1997)	acquirer'), hereby declare that the transferor (Dr. Saloni Satish Wagh) and transferee have		
10.	exemptions has been duly complied with.	Yes, all the conditions specified under regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 with respect exemptions has been duly complied with.		

11.	Shareholding details		Before the proposed transaction		After the proposed transaction	
		No. of shares /voting rights	% w.r.t total share capital of TC	No. of shares /voting rights	% w.r.t total share capital of TC	
	a	Acquirer(s) and PACs (other than sellers) (*)				or re
		Shivani Satish Wagh	29,250	0.04	1,02,375	0.13
		Satish Waman Wagh	5,44,41,205	67.64	5,44,41,205	67.64
		Smita Satish Wagh	3,21,750	0.40	3,21,750	0.40
		Supriya Pharmaceuticals	10	0.00	10	0.00
	b	Seller (s)	1,75,500	0.22	1,02,375	0.13

Note:

A agy

^(*) Shareholding of each entity may be shown separately and then collectively in a group. The above disclosure shall be signed by the acquirer mentioning date & place. In case, there is more than one acquirer, the report shall be signed either by all the persons or by aperson duly authorized to do so on behalf of all the acquirers.